WAVE LIFE SCIENCES LTD. Financing Cash Flow
WAVE LIFE SCIENCES LTD. (WVE) reported Financing Cash Flow of $2.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-07-30
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $330.00K, a 97.18% decline year-over-year.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.53M, a 39.18% decline year-over-year.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $439.69M, a 1156.95% increase year-over-year.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $32.69M, a 83.95% decline year-over-year.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2025 was $488.24M, a 92.30% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2024 was $253.89M, a 91.57% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2023 was $132.53M, a 97.26% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. net cash provided by (used in) financing activities for fiscal 2022 was $67.19M, a 20.35% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $330.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.86M 10-Q · filed 2026-07-30 | $442.55M derived: sum of 3 quarters · filed 2026-07-30 | $475.24M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $2.53M 10-Q · filed 2026-04-28 | $442.22M derived: sum of 2 quarters · filed 2026-04-28 | $474.91M derived: sum of 3 quarters · filed 2026-04-28 | $486.61M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $439.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $472.39M derived: sum of 2 quarters · filed 2026-02-26 | $484.08M derived: sum of 3 quarters · filed 2026-07-30 | $488.24M 10-K · filed 2026-02-26 |
| 2025-09-30 | $32.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $44.38M derived: sum of 2 quarters · filed 2026-07-30 | $48.54M 10-Q · filed 2025-11-10 | $83.52M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $11.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $15.85M 10-Q · filed 2026-07-30 | $50.83M derived: sum of 3 quarters · filed 2026-07-30 | $254.57M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $4.16M 10-Q · filed 2026-04-28 | $39.14M derived: sum of 2 quarters · filed 2026-04-28 | $242.88M derived: sum of 3 quarters · filed 2026-04-28 | $243.53M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $238.73M derived: sum of 2 quarters · filed 2026-02-26 | $239.38M derived: sum of 3 quarters · filed 2026-02-26 | $253.89M 10-K · filed 2026-02-26 |
| 2024-09-30 | $203.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $204.40M derived: sum of 2 quarters · filed 2025-11-10 | $218.91M 10-Q · filed 2025-11-10 | $312.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $653.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $15.16M 10-Q · filed 2025-07-30 | $109.13M derived: sum of 3 quarters · filed 2026-02-26 | $110.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $14.51M 10-Q · filed 2025-05-08 | $108.47M derived: sum of 2 quarters · filed 2026-02-26 | $110.14M derived: sum of 3 quarters · filed 2026-02-26 | $111.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $93.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.63M derived: sum of 2 quarters · filed 2026-02-26 | $97.48M derived: sum of 3 quarters · filed 2026-02-26 | $132.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.52M derived: sum of 2 quarters · filed 2024-11-12 | $38.57M 10-Q · filed 2024-11-12 | $38.63M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $36.90M 10-Q · filed 2024-08-08 | $36.96M derived: sum of 3 quarters · filed 2025-03-04 | $36.97M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $35.05M 10-Q · filed 2024-05-10 | $35.11M derived: sum of 2 quarters · filed 2025-03-04 | $35.13M derived: sum of 3 quarters · filed 2025-03-04 | $100.92M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $72.00K derived: sum of 2 quarters · filed 2025-03-04 | $65.87M derived: sum of 3 quarters · filed 2025-03-04 | $67.19M 10-K · filed 2025-03-04 |
| 2022-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $65.82M derived: sum of 2 quarters · filed 2023-11-09 | $67.13M 10-Q · filed 2023-11-09 | $100.93M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $65.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $67.12M 10-Q · filed 2023-08-03 | $100.91M derived: sum of 3 quarters · filed 2023-08-03 | $109.26M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.32M 10-Q · filed 2023-05-03 | $35.11M derived: sum of 2 quarters · filed 2023-05-03 | $43.46M derived: sum of 3 quarters · filed 2023-05-03 | $48.50M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $33.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $42.14M derived: sum of 2 quarters · filed 2023-03-23 | $47.19M derived: sum of 3 quarters · filed 2023-03-23 | $55.83M 10-K · filed 2023-03-23 |
| 2021-09-30 | $8.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $13.39M derived: sum of 2 quarters · filed 2022-11-10 | $22.04M 10-Q · filed 2022-11-10 | $22.05M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $5.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $13.69M 10-Q · filed 2022-08-11 | $13.71M derived: sum of 3 quarters · filed 2022-08-11 | $156.23M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $8.64M 10-Q · filed 2022-05-12 | $8.66M derived: sum of 2 quarters · filed 2022-05-12 | $151.18M derived: sum of 3 quarters · filed 2022-05-12 | $162.56M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $142.54M derived: sum of 2 quarters · filed 2022-03-03 | $153.92M derived: sum of 3 quarters · filed 2022-03-03 | $154.54M 10-K · filed 2022-03-03 |
| 2020-09-30 | $142.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $153.91M derived: sum of 2 quarters · filed 2021-11-10 | $154.52M 10-Q · filed 2021-11-10 | $155.28M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $11.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $12.00M 10-Q · filed 2021-08-05 | $12.75M derived: sum of 3 quarters · filed 2021-08-05 | $13.01M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $614.00K 10-Q · filed 2021-05-13 | $1.37M derived: sum of 2 quarters · filed 2021-05-13 | $1.62M derived: sum of 3 quarters · filed 2021-05-13 | $1.47M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $757.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.01M derived: sum of 2 quarters · filed 2021-03-04 | $853.00K derived: sum of 3 quarters · filed 2021-03-04 | $164.40M 10-K · filed 2021-03-04 |
| 2019-09-30 | $253.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $96.00K derived: sum of 2 quarters · filed 2020-11-09 | $163.64M 10-Q · filed 2020-11-09 | $164.29M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $163.39M 10-Q · filed 2020-08-10 | $164.03M derived: sum of 3 quarters · filed 2020-08-10 | $165.39M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $163.55M 10-Q · filed 2020-05-11 | $164.19M derived: sum of 2 quarters · filed 2020-05-11 | $165.54M derived: sum of 3 quarters · filed 2020-05-11 | $227.10M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $646.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $2.00M derived: sum of 2 quarters · filed 2020-03-02 | $63.56M derived: sum of 3 quarters · filed 2020-03-02 | $65.09M 10-K · filed 2020-03-02 |
| 2018-09-30 | $1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $62.91M derived: sum of 2 quarters · filed 2019-11-05 | $64.45M 10-Q · filed 2019-11-05 | $65.04M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $61.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $63.10M 10-Q · filed 2019-08-06 | $63.69M derived: sum of 3 quarters · filed 2020-03-02 | $63.74M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $1.54M 10-Q · filed 2019-05-10 | $2.13M derived: sum of 2 quarters · filed 2020-03-02 | $2.19M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $648.00K derived: sum of 2 quarters · filed 2020-03-02 | $94.37M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $93.78M 10-Q · filed 2018-11-09 | ||
| 2017-06-30 | $93.73M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $29.12M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |